Abstract library

4 results for "Van Leeuwaarde".
#1858 Quality of Life in Patients with Multiple Endocrine Neoplasia Type I (MEN1): Results from the Dutch MEN1 Study Group
Introduction: Multiple Endocrine neoplasia type 1 (MEN1) is a hereditary tumor syndrome, characterized by an increased lifetime risk of benign and malignant endocrine tumors in various organs. Data on quality of life (QoL) in patients with MEN1 are scarce, whereas QoL is considered an important treatment outcome.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: ...none of the above
Presenting Author: MD Rachel van Leeuwaarde
Keywords: MEN1, QoL
#2122 Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?
Introduction: Quality of life (QoL) is important to all cancer patients. The EORTC QLQ-QNET21 is the most commonly used questionnaire in patients with neuroendocrine tumors (NETs).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MD Rachel van Leeuwaarde
#2731 177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)
Introduction: The liver is the most commonly affected organ in metastatic neuroendocrine disease and is the most incriminating factor for patient survival. Additional treatment of liver disease with radioembolization may improve outcome in NET patients with bulky residual liver disease after PRRT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: M.D. Ph.D. Arthur Braat
Authors: Braat A, Rutger B, Van Rooij R, Braat M, ...
#3034 Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is ≥ 10%?
Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Teresa Alonso Gordoa